JP2020525032A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525032A5
JP2020525032A5 JP2019572485A JP2019572485A JP2020525032A5 JP 2020525032 A5 JP2020525032 A5 JP 2020525032A5 JP 2019572485 A JP2019572485 A JP 2019572485A JP 2019572485 A JP2019572485 A JP 2019572485A JP 2020525032 A5 JP2020525032 A5 JP 2020525032A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
immune effector
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525032A (ja
Filing date
Publication date
Priority claimed from PCT/CN2017/090343 external-priority patent/WO2019000223A1/en
Application filed filed Critical
Publication of JP2020525032A publication Critical patent/JP2020525032A/ja
Publication of JP2020525032A5 publication Critical patent/JP2020525032A5/ja
Pending legal-status Critical Current

Links

JP2019572485A 2017-06-27 2018-06-27 キメラ抗体免疫エフェクター細胞エンゲージャー及びその使用方法 Pending JP2020525032A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/090343 2017-06-27
PCT/CN2017/090343 WO2019000223A1 (en) 2017-06-27 2017-06-27 ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
PCT/CN2018/093135 WO2019001474A1 (en) 2017-06-27 2018-06-27 ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2020525032A JP2020525032A (ja) 2020-08-27
JP2020525032A5 true JP2020525032A5 (enExample) 2021-07-26

Family

ID=64740850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572485A Pending JP2020525032A (ja) 2017-06-27 2018-06-27 キメラ抗体免疫エフェクター細胞エンゲージャー及びその使用方法

Country Status (6)

Country Link
US (1) US11827713B2 (enExample)
EP (1) EP3645574A4 (enExample)
JP (1) JP2020525032A (enExample)
CN (1) CN110719919A (enExample)
TW (1) TW201906867A (enExample)
WO (2) WO2019000223A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
HRP20240767T1 (hr) 2016-09-14 2024-09-13 Teneoone, Inc. Cd3 vezujuća antitijela
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
MX2021012205A (es) 2019-04-05 2022-02-21 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma.
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CR20210576A (es) 2019-05-21 2021-12-15 Novartis Ag Moléculas de unión a cd19 y usos de las mismas
TWI872082B (zh) 2019-06-14 2025-02-11 美商泰尼歐生物公司 與c d 2 2 及c d 3 結合之多特異性重鏈抗體
WO2021043169A1 (zh) * 2019-09-02 2021-03-11 成都盛世君联生物技术有限公司 特异性结合b细胞成熟抗原的抗体及其用途
CN115052901B (zh) * 2019-12-16 2025-12-09 南京传奇生物科技有限公司 靶向bcma的单结构域抗体和嵌合抗原受体及其使用方法
IL299027A (en) * 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
CN111848798B (zh) * 2020-07-27 2022-05-13 源道隆(苏州)医学科技有限公司 可结合bcma的纳米抗体及其应用
WO2022098771A1 (en) * 2020-11-03 2022-05-12 Ab Studio Inc. Multispecific antibodies and uses thereof
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN117120471A (zh) * 2021-03-23 2023-11-24 广州凌腾生物医药有限公司 结合cd3的多特异性抗原结合蛋白及其用途
MX2024002954A (es) * 2021-09-08 2024-03-26 Ksq Therapeutics Inc Ensayo de potencia de linfocitos.
US20230227575A1 (en) * 2022-01-10 2023-07-20 Expression Therapeutics, Llc Engineered T Cells
AU2023348527A1 (en) * 2022-09-30 2025-04-24 Nona Biosciences (Suzhou) Co., Ltd. Cd3-targeting antibody and use thereof
JP2025539364A (ja) * 2022-11-22 2025-12-05 エクスプレッション セラピューティクス, エルエルシー 遺伝子操作t細胞
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN118994391A (zh) * 2023-05-16 2024-11-22 亘喜生物科技(上海)有限公司 特异性结合cd38的抗体及其制法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
ATE203767T1 (de) 1992-08-21 2001-08-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2281837B1 (en) 2001-08-10 2016-10-05 Aberdeen University Antigen binding domains from fish
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
NZ547279A (en) 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP1991580A2 (en) 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
BRPI0713000A8 (pt) * 2006-06-12 2017-12-05 Trubion Pharmaceuticals Inc Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
EP2155783B2 (en) 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
JP5593641B2 (ja) 2009-06-26 2014-09-24 味の素株式会社 減塩飲食品用組成物
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bcma発現に相関性を有する疾患を治療する因子及び方法
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
HK1203393A1 (en) 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
DK2857420T3 (da) * 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd Målvævsspecifikt antigenbindende molekyle
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドXencor、 Inc. Cd38及びcd3に結合する二重特異性抗体
SG11201700492SA (en) * 2014-07-24 2017-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
MX2017006918A (es) * 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN107847559B (zh) 2015-05-13 2022-07-01 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
EP3115376B1 (en) 2015-07-10 2018-09-05 Merus N.V. Human cd3 binding antibody
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JO3799B1 (ar) * 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
IL266892B2 (en) * 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
MA55562A (fr) * 2019-04-05 2022-02-09 2Seventy Bio Inc Production de cellules car-t anti-bcma

Similar Documents

Publication Publication Date Title
JP2020525032A5 (enExample)
CN112969476B (zh) 多特异性蛋白分子
JP2012501670A5 (enExample)
JP2019520797A5 (enExample)
JP2019201643A5 (enExample)
JP2013545455A5 (enExample)
JP2012501669A5 (enExample)
TW201837174A (zh) 抗gprc5d抗體及包含該抗體之分子
JP2017532952A5 (enExample)
JP2019513777A5 (enExample)
JP2020501531A5 (enExample)
JP2021503455A5 (enExample)
JP2017504578A5 (enExample)
JPWO2019129221A5 (enExample)
JP2015163068A5 (enExample)
JP2013502913A5 (enExample)
JP2018521638A5 (enExample)
JP2019501883A5 (enExample)
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2018527919A5 (enExample)
JP2017535257A5 (enExample)
JP2018522888A5 (enExample)
JP2011509245A5 (enExample)
JP2016536322A5 (enExample)
JP2018507188A5 (enExample)